United States Pharmaceutical Supply Chain Review Act

senate

house

president

Introduced on September 25, 2024 by Elizabeth Warren

Legislation Details

Requires the Federal Trade Commission (FTC) to submit a report on foreign investment in the U.S. pharmaceutical industry.
The report must be submitted within one year of enactment and annually thereafter.
The FTC will consult with the Secretary of Commerce and other relevant entities while preparing the report.
The report will assess:
- The supply chain of the pharmaceutical industry and the impact of foreign manufacturing reliance.
- The effect of foreign investment on domestic drug production capacity.
- The impact of foreign investment in DNA sequencing and storage technologies on U.S. capabilities.
- The consequences of U.S. pharmaceutical manufacturers relocating facilities abroad on domestic production capacity.
The FTC is authorized to conduct necessary studies under the Federal Trade Commission Act.
An unclassified summary of the report will be published on the FTC’s publicly available website.
Defines “appropriate congressional committees” involved in the oversight of the report.

Last updated 11/5/2024

Requires the Federal Trade Commission (FTC) to submit a report on foreign investment in the U.S. pharmaceutical industry.
The report must be submitted within one year of enactment and annually thereafter.
The FTC will consult with the Secretary of Commerce and other relevant entities while preparing the report.
The report will assess:
- The supply chain of the pharmaceutical industry and the impact of foreign manufacturing reliance.
- The effect of foreign investment on domestic drug production capacity.
- The impact of foreign investment in DNA sequencing and storage technologies on U.S. capabilities.
- The consequences of U.S. pharmaceutical manufacturers relocating facilities abroad on domestic production capacity.
The FTC is authorized to conduct necessary studies under the Federal Trade Commission Act.
An unclassified summary of the report will be published on the FTC’s publicly available website.
Defines “appropriate congressional committees” involved in the oversight of the report.